Skip to main content

Exelixis, Inc.

EXEL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000939767

In the last 90 days, Exelixis, Inc. insiders filed 0 open-market purchases and 1 sale; 760 institutions reported holding it in 13F filings for Q2 2026, worth $14.1B in total; no superinvestor holds it.

Holders of 5% or more of EXEL

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Exelixis, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of EXEL
HolderLatest formStakeChangeFirst filedLatest filingFiling
BlackRock, Inc.13G/A10.20%28.5M shares–Apr 28, 20251 filingApr 28, 2025SEC
Farallon Capital Partners, L.P.13D/A5.90%15.7M shares−0.90 ppfrom 6.80%Mar 5, 20253 filingsJan 5, 2026SEC
Farallon Capital Management, L.L.C.13D/A5.60%14.0M shares–Aug 14, 20261 filingAug 14, 2026SEC
Vanguard Capital Management LLC13G5.09%13.2M sharesNewApr 29, 20261 filingApr 29, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

19 Schedule 13D and 13G filings on Exelixis, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on EXEL
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 14, 20268:21 AM ETFarallon Capital Management, L.L.C.and 28 others13D/A5.60%14.0M shares–Aug 14, 2026SEC
Aug 12, 20267:17 AM ETAQR Capital Management LLCand 1 other13G/A4.39%11.0M shares−0.70 ppfrom 5.09%Below 5%Jun 30, 2026SEC
Apr 29, 20266:49 PM ETVanguard Capital Management LLC13G5.09%13.2M sharesNewMar 31, 2026SEC
Mar 26, 20266:23 PM ETVanguard Group Inc13G/A0.00%0 shares–Below 5%Mar 13, 2026SEC
Feb 13, 202611:37 AM ETAQR Capital Management LLCand 1 other13G5.09%13.7M sharesNewDec 31, 2025SEC
Jan 5, 20266:05 PM ETFarallon Capital Partners, L.P.and 30 others13D/A5.90%15.7M shares−0.90 ppfrom 6.80%Jan 1, 2026SEC
May 20, 20255:59 PM ETFarallon Capital Partners, L.P.and 29 others13D/A6.80%18.6M shares−1.60 ppfrom 8.40%May 16, 2025SEC
Apr 28, 202510:24 AM ETBlackRock, Inc.13G/A10.20%28.5M shares–Mar 31, 2025SEC
Mar 5, 20255:01 PM ETFarallon Capital Partners, L.P.and 29 others13D/A8.40%23.4M shares–Mar 5, 2025SEC
Feb 14, 2022Price T Rowe Associates Inc13G/AOld format–––SEC
Feb 11, 2022Renaissance Technologies LLC13G/AOld format–––SEC
Feb 10, 2022Vanguard Group Inc13G/AOld format–––SEC
Feb 9, 2022FMR LLC13GOld format–New–SEC
Jan 27, 20222:15 PM ETBlackRock Inc.13G/AOld format–––SEC
Jan 25, 20226:40 PM ETBlackRock Inc.13G/AOld format–––SEC
Feb 16, 2021Price T Rowe Associates Inc13GOld format–New–SEC
Feb 11, 2021Renaissance Technologies LLC13G/AOld format–––SEC
Feb 10, 2021Vanguard Group Inc13G/AOld format–––SEC
Jan 26, 20217:14 PM ETBlackRock Inc.13G/AOld format–––SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Exelixis, Inc. shares.

No Form 144 notices for Exelixis, Inc. are on file.